What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables

Immunotherapy targeting the PD-1–PD-L1 axis yielded good results in treating different immunologically ‘‘hot’’ tumors. A phase II study revealed good therapeutic activity of pembrolizumab in selected prostatic carcinoma (PC)-patients. We performed a systematic literature review (PRISMA guidelines),...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andrea Palicelli, Martina Bonacini, Stefania Croci, Cristina Magi-Galluzzi, Sofia Cañete-Portillo, Alcides Chaux, Alessandra Bisagni, Eleonora Zanetti, Dario De Biase, Beatrice Melli, Francesca Sanguedolce, Moira Ragazzi, Maria Paola Bonasoni, Alessandra Soriano, Stefano Ascani, Maurizio Zizzo, Carolina Castro Ruiz, Antonio De Leo, Guido Giordano, Matteo Landriscina, Giuseppe Carrieri, Luigi Cormio, Daniel M. Berney, Daniel Athanazio, Jatin Gandhi, Alberto Cavazza, Giacomo Santandrea, Alessandro Tafuni, Magda Zanelli
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	PD-L1 prostate cancer adenocarcinoma immunohistochemistry target-therapy Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/bb8e29accbd74f43b44ae3429430e2c6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bb8e29accbd74f43b44ae3429430e2c6
record_format	dspace
spelling	oai:doaj.org-article:bb8e29accbd74f43b44ae3429430e2c62021-11-25T17:12:13ZWhat Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables10.3390/cells101131662073-4409https://doaj.org/article/bb8e29accbd74f43b44ae3429430e2c62021-11-01T00:00:00Zhttps://www.mdpi.com/2073-4409/10/11/3166https://doaj.org/toc/2073-4409Immunotherapy targeting the PD-1–PD-L1 axis yielded good results in treating different immunologically ‘‘hot’’ tumors. A phase II study revealed good therapeutic activity of pembrolizumab in selected prostatic carcinoma (PC)-patients. We performed a systematic literature review (PRISMA guidelines), which analyzes the immunohistochemical expression of PD-L1 in human PC samples and highlights the pre-analytical and interpretation variables. Interestingly, 29% acinar PCs, 7% ductal PCs, and 46% neuroendocrine carcinomas/tumors were PD-L1+ on immunohistochemistry. Different scoring methods or cut-off criteria were applied on variable specimen-types, evaluating tumors showing different clinic-pathologic features. The positivity rate of different PD-L1 antibody clones in tumor cells ranged from 3% (SP142) to 50% (ABM4E54), excluding the single case tested for RM-320. The most tested clone was E1L3N, followed by 22C3 (most used for pembrolizumab eligibility), SP263, SP142, and 28-8, which gave the positivity rates of 35%, 11–41% (depending on different scoring systems), 6%, 3%, and 15%, respectively. Other clones were tested in <200 cases. The PD-L1 positivity rate was usually higher in tumors than benign tissues. It was higher in non-tissue microarray specimens (41–50% vs. 15%), as PC cells frequently showed heterogenous or focal PD-L1-staining. PD-L1 was expressed by immune or stromal cells in 12% and 69% cases, respectively. Tumor heterogeneity, inter-institutional preanalytics, and inter-observer interpretation variability may account for result biases.Andrea PalicelliMartina BonaciniStefania CrociCristina Magi-GalluzziSofia Cañete-PortilloAlcides ChauxAlessandra BisagniEleonora ZanettiDario De BiaseBeatrice MelliFrancesca SanguedolceMoira RagazziMaria Paola BonasoniAlessandra SorianoStefano AscaniMaurizio ZizzoCarolina Castro RuizAntonio De LeoGuido GiordanoMatteo LandriscinaGiuseppe CarrieriLuigi CormioDaniel M. BerneyDaniel AthanazioJatin GandhiAlberto CavazzaGiacomo SantandreaAlessandro TafuniMagda ZanelliMDPI AGarticlePD-L1prostatecanceradenocarcinomaimmunohistochemistrytarget-therapyBiology (General)QH301-705.5ENCells, Vol 10, Iss 3166, p 3166 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	PD-L1 prostate cancer adenocarcinoma immunohistochemistry target-therapy Biology (General) QH301-705.5
spellingShingle	PD-L1 prostate cancer adenocarcinoma immunohistochemistry target-therapy Biology (General) QH301-705.5 Andrea Palicelli Martina Bonacini Stefania Croci Cristina Magi-Galluzzi Sofia Cañete-Portillo Alcides Chaux Alessandra Bisagni Eleonora Zanetti Dario De Biase Beatrice Melli Francesca Sanguedolce Moira Ragazzi Maria Paola Bonasoni Alessandra Soriano Stefano Ascani Maurizio Zizzo Carolina Castro Ruiz Antonio De Leo Guido Giordano Matteo Landriscina Giuseppe Carrieri Luigi Cormio Daniel M. Berney Daniel Athanazio Jatin Gandhi Alberto Cavazza Giacomo Santandrea Alessandro Tafuni Magda Zanelli What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables
description	Immunotherapy targeting the PD-1–PD-L1 axis yielded good results in treating different immunologically ‘‘hot’’ tumors. A phase II study revealed good therapeutic activity of pembrolizumab in selected prostatic carcinoma (PC)-patients. We performed a systematic literature review (PRISMA guidelines), which analyzes the immunohistochemical expression of PD-L1 in human PC samples and highlights the pre-analytical and interpretation variables. Interestingly, 29% acinar PCs, 7% ductal PCs, and 46% neuroendocrine carcinomas/tumors were PD-L1+ on immunohistochemistry. Different scoring methods or cut-off criteria were applied on variable specimen-types, evaluating tumors showing different clinic-pathologic features. The positivity rate of different PD-L1 antibody clones in tumor cells ranged from 3% (SP142) to 50% (ABM4E54), excluding the single case tested for RM-320. The most tested clone was E1L3N, followed by 22C3 (most used for pembrolizumab eligibility), SP263, SP142, and 28-8, which gave the positivity rates of 35%, 11–41% (depending on different scoring systems), 6%, 3%, and 15%, respectively. Other clones were tested in <200 cases. The PD-L1 positivity rate was usually higher in tumors than benign tissues. It was higher in non-tissue microarray specimens (41–50% vs. 15%), as PC cells frequently showed heterogenous or focal PD-L1-staining. PD-L1 was expressed by immune or stromal cells in 12% and 69% cases, respectively. Tumor heterogeneity, inter-institutional preanalytics, and inter-observer interpretation variability may account for result biases.
format	article
author	Andrea Palicelli Martina Bonacini Stefania Croci Cristina Magi-Galluzzi Sofia Cañete-Portillo Alcides Chaux Alessandra Bisagni Eleonora Zanetti Dario De Biase Beatrice Melli Francesca Sanguedolce Moira Ragazzi Maria Paola Bonasoni Alessandra Soriano Stefano Ascani Maurizio Zizzo Carolina Castro Ruiz Antonio De Leo Guido Giordano Matteo Landriscina Giuseppe Carrieri Luigi Cormio Daniel M. Berney Daniel Athanazio Jatin Gandhi Alberto Cavazza Giacomo Santandrea Alessandro Tafuni Magda Zanelli
author_facet	Andrea Palicelli Martina Bonacini Stefania Croci Cristina Magi-Galluzzi Sofia Cañete-Portillo Alcides Chaux Alessandra Bisagni Eleonora Zanetti Dario De Biase Beatrice Melli Francesca Sanguedolce Moira Ragazzi Maria Paola Bonasoni Alessandra Soriano Stefano Ascani Maurizio Zizzo Carolina Castro Ruiz Antonio De Leo Guido Giordano Matteo Landriscina Giuseppe Carrieri Luigi Cormio Daniel M. Berney Daniel Athanazio Jatin Gandhi Alberto Cavazza Giacomo Santandrea Alessandro Tafuni Magda Zanelli
author_sort	Andrea Palicelli
title	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables
title_short	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables
title_full	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables
title_fullStr	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables
title_full_unstemmed	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables
title_sort	what do we have to know about pd-l1 expression in prostate cancer? a systematic literature review. part 1: focus on immunohistochemical results with discussion of pre-analytical and interpretation variables
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/bb8e29accbd74f43b44ae3429430e2c6
work_keys_str_mv	AT andreapalicelli whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT martinabonacini whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT stefaniacroci whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT cristinamagigalluzzi whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT sofiacaneteportillo whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT alcideschaux whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT alessandrabisagni whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT eleonorazanetti whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT dariodebiase whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT beatricemelli whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT francescasanguedolce whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT moiraragazzi whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT mariapaolabonasoni whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT alessandrasoriano whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT stefanoascani whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT mauriziozizzo whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT carolinacastroruiz whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT antoniodeleo whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT guidogiordano whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT matteolandriscina whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT giuseppecarrieri whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT luigicormio whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT danielmberney whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT danielathanazio whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT jatingandhi whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT albertocavazza whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT giacomosantandrea whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT alessandrotafuni whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables AT magdazanelli whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart1focusonimmunohistochemicalresultswithdiscussionofpreanalyticalandinterpretationvariables
_version_	1718412674136539136

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables

Ejemplares similares